Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
STEVENAGE, United Kingdom, March 26, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.
- STEVENAGE, United Kingdom, March 26, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.
- Ali has extensive experience in the biotechnology and pharma sector working with both private and public companies.
- David Venables, CEO of Laverock, said: “Ali has an exceptional track record working with innovative biotechnology and pharma companies.
- The management team and Board are exceptionally strong, and I believe we have a very solid foundation from which to deliver on the promise.”
For further information please contact: